Daiichi Sankyo and Merck report phase 2 trial results for lung cancer drug
Director Frank R. Martire of Cannae Holdings, Inc. (NYSE:CNNE) sold a total of 133,333 shares of common stock in two transactions, with the total value of $2.48 million. According to InvestingPro data, the company appears undervalued at its current market cap of $1.05 billion, despite facing profitability challenges with negative earnings in the last twelve months.
The first sale, which occurred on August 29, 2025, involved 106,855 shares sold at an average price of $18.629, with prices ranging from $18.59 to $18.74. The second sale took place on September 2, 2025, with 26,478 shares sold at an average price of $18.434, with prices ranging from $18.33 to $18.59. While this insider selling occurs, InvestingPro analysis shows the company maintains strong liquidity with a current ratio of 2.78, indicating solid short-term financial health.
Following these transactions, Martire directly holds 199,619 shares of Cannae Holdings. The sales were executed indirectly through the Frank and Marisa Martire 2012 Florida Trust. Notably, InvestingPro research reveals management has been actively buying back shares, with additional insights available in the comprehensive Pro Research Report covering 1,400+ US stocks.
In other recent news, Cannae Holdings Inc. announced its second-quarter earnings for 2025, showcasing mixed financial results. The company reported an earnings per share (EPS) of -$0.18, which was better than the anticipated -$0.27, indicating a positive surprise of 33.33%. Despite this, Cannae Holdings’ revenue came in slightly below expectations at $110.2 million, compared to the forecasted $111.1 million. No significant mergers or acquisitions were reported in this period. Additionally, there have been no recent upgrades or downgrades from major analyst firms concerning Cannae Holdings. These developments provide investors with a detailed look at the company’s recent financial performance and market position.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.